| Literature DB >> 30659228 |
Hae Seong Song1, Young Ho Song2, Nem Singh2, Hyunuk Kim3, Hyelin Jeon1, Inhye Kim4, Se Chan Kang5, Ki-Whan Chi6.
Abstract
We report herein on the design, synthesis and biological activity of Ru-based self-assembled supramolecular bowls as a potent antiEntities:
Year: 2019 PMID: 30659228 PMCID: PMC6338755 DOI: 10.1038/s41598-018-36755-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Structure of molecular bowls. (a) Coordination-driven self-assembly molecular bowls 6–9. (b) X-ray crystal structure of 6 in ball and stick model, (c) space-filling representation superimposing capped stick. Counter-anions and hydrogen atoms are omitted for clarity.
Screening of molecular bowls inhibitory effect on various cancer cells growth (IC50: μM).
| Sample | AGS | A549 | HCT-15 | SK-HEP-1 | HepG2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 24 h | 48 h | 24 h | 24 h | 24 h | 48 h | 24 h | 48 h | 24 h | 48 h | |
| Dipyridyl benzamide donor 1 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80.02 ± 4.248 | 100 | 88.13 ± 2.324 |
| Dinuclear Ru(II) acceptor 2 | 100 | 98.33 ± 4.218 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Dinuclear Ru(II) acceptor 3 | 100 | 76.08 ± 4.683 | 100 | 99.39 ± 5.108 | 100 | 100 | 100 | 85.63 ± 3.668 | 100 | 84.67 ± 5.462 |
| Dinuclear Ru(II) acceptor 4 | 87.26 ± 4.167 | 75.22 ± 3.529 | 100 | 100 | 90.63 ± 5.873 | 79.26 ± 3.438 | 81.26 ± 4.576 | 70.27 ± 2.352 | 82.67 ± 3.442 | 80.22 ± 2.884 |
| Dinuclear Ru(II) acceptor 5 | 100 | 100 | 100 | 100 | 100 | 68.22 ± 2.287 | 100 | 72.25 ± 2.323 | 100 | 78.28 ± 2.664 |
| Molecular bowl 6 | 24.73 ± 4.034 | 4.14 ± 0.146 | 100 | 60.27 ± 9.116 | 60.27 ± 9.116 | 64.89 ± 6.744 | 60.27 ± 9.116 | 17.87 ± 0.465 | 63.24 ± 5.287 | 20.87 ± 2.002 |
| Molecular bowl 7 | 29.40 ± 1.909 | 5.32 ± 0.493 | 100 | 19.53 ± 4.352 | 19.53 ± 4.352 | 38.89 ± 10.87 | 19.53 ± 4.352 | 27.87 ± 4.403 | 18.63 ± 2.116 | 22.67 ± 1.537 |
| Molecular bowl 8 | 5.10 ± 0.388 | 1.39 ± 0.018 | 100 | 5.12 ± 0.125 | 5.12 ± 0.125 | 1.57 ± 0.029 | 5.12 ± 0.125 | 1.56 ± 0.031 | 1.09 ± 0.019 | 0.78 ± 0.004 |
| Molecular bowl 9 | 100 | 4.35 ± 0.224 | 100 | 100 | 100 | 13.64 ± 4.776 | 100 | 7.79 ± 1.825 | 84.64 ± 2.014 | 18.98 ± 1.121 |
| Cisplatin | 90.97 ± 4.337 | 4.84 ± 0.350 | 100 | 33.94 ± 1.498 | 33.94 ± 1.498 | 30.03 ± 0.215 | 33.94 ± 1.498 | 11.70 ± 1.077 | 20.89 ± 0.892 | 12.03 ± 2.646 |
Figure 2MB8 induces β-oxidation by activating SCAD, MCAD and LCAD. (a) GeneFishingTM DEG screening results. Indicated band was overexpressed by MB8. HepG2 cells (2 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), for 24 h. (b) mRNA expression of genes detected by qRT-PCR. (c) The protein level was analyzed by Western blot. (d) Densitometric analysis of Western blots is represented as the mean band density. Representative data are shown as the mean ± standard error of the mean (SEM) of each group. *P < 0.05 compared with the control.
Figure 3MB8 suppresses hypoxia by inhibiting the expression of HIF-1α and PDHK-1, while activates glucose transport by altering GLUT4. HepG2 cells (4 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), and when it was 24 h. (a) The protein levels were analyzed by Western blot. (b–d) Densitometric analysis of Western blots is represented as the mean band density. (e,f) mRNA expression of GLUT1 and GLUT4 were detected by qRT-PCR. Representative data are shown as the mean ± standard error of the mean (SEM) of each group. *P < 0.05 compared with the control.
Figure 4MB8 activates electron transport system by increasing cytochrome c oxidase (COX) subunits. HepG2 cells (4 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), and when it was 24 h, the level of mRNA expression was confirmed. (a–h) mRNA expression of COXs was detected by qRT-PCR. Representative data are shown as the mean ± standard error of the mean (SEM) of each group. *P < 0.05 compared with the control.
Figure 5MB8 induces ROS overexpression. HepG2 cells (2 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), and when it was 24 h. The top panel shows microscopic images of DCF-DA fluorescence intensity that reflect the ROS level in HepG2 cells. Representative data are shown as the mean ± standard error of the mean (SEM) of each group. *P < 0.05 compared with the control.
Figure 6MB8 induces apoptosis by activating the extrinsic and intrinsic pathway in HepG2 cells. (a) HepG2 cells (2 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), and when it was 24 h. Apoptotic and necrotic cells were stained with green and red, respectively. (b) HepG2 cells (4 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by concentration (1, 2 and 4 μM), and when it was 24 h. The protein levels were analyzed by Western blot. (c–h) Densitometric analysis of Western blots is represented as the mean band density. (i) HepG2 cells (2 × 105 cells/well) were seeded on a 6-well plate and incubated for 24 h. After that, MB8 was treated by 4 μM, and when it was treated by times 12, 24 and 48 h. Cytochrome c levels were measured using cytochrome c ELISA kit. Representative data are shown as the mean ± standard error of the mean (SEM) of each group. *P < 0.05 compared with the control.
Figure 7Schematic diagram showing the apoptosis effects of MB8 in HepG2 cell. Increasing the expression of GLUT4 protein as well as promoting β-oxidation of fatty acids, thereby activating the TCA cycle in the mitochondria and increasing the production of ROS. These signal transduction activates the intrinsic apoptosis pathway, and cleavage of caspase 8 activates the extrinsic apoptosis pathway. Through these various pathways, MB8 induces strong apoptosis in HCC.
The primer sequences used for real-time PCR.
| Gene name | Primer sequences |
|---|---|
| SCAD | 5′- CGGCAGTTACACACCATCTAC-3′ (forward) |
| 5′- GCAATGGGAAACAACTCCTTCTC-3′ (reverse) | |
| MCAD | 5′- GGAAGCAGATACCCCAGGAAT-3′ (forward) |
| 5′- AGCTCCGTCACCAATTAAAACAT-3′ (reverse) | |
| LCAD | 5′- TGCAATAGCAATGACAGAGCC-3′ (forward) |
| 5′- CGCAACTACAATCACAACATCAC-3′ (reverse) | |
| VLCAD | 5′- TCAGAGCATCGGTTTCAAAGG-3′ (forward) |
| 5′- AGGGCTCGGTTAGACAGAAAG-3′ (reverse) | |
| GLUT-1 | 5′- CCATCCACCACACTCACCAC-3′ (forward) |
| 5′- GCCCAGGATCAGCATCTCAA-3′ (reverse) | |
| GLUT-4 | 5′- AGAGTCTAAAGCGCCT-3′ (forward) |
| 5′- CCGAGACCAACGTGAA-3′ (reverse) | |
| COX-1 | 5′- GGCCTGACTGGCATTGTATT-3′ (forward) |
| 5′- TGGCGTAGGTTTGGTCTAGG-3′ (reverse) | |
| COX-2 | 5′- ACAGACGAGGTCAACGATCC-3′ (forward) |
| 5′- TCGATTGTCAACGTCAAGGA-3′ (reverse) | |
| COX-3 | 5′- CCCGCTAAATCCCCTAGAAG-3′ (forward) |
| 5′- ATGGTGAAGGGAGACTCGAA-3′ (reverse) | |
| COX-4 | 5′- GCCCATGTCAAGCACCTGTC-3′ (forward) |
| 5′- CCCTGTTCATCTCAGCAAAGCTC-3′ (reverse) | |
| COX-5 | 5′- GATGCGCTCCATGGCATCT-3′ (forward) |
| 5′- TCTTTGCAGCCAGCATGATCTC-3′ (reverse) | |
| COX 6 | 5′- GGCTGTAGCATTCGTGCTATCC-3′ (forward) |
| 5′- TCTGAAAGATACCAGCCTTCCTCA-3′ (reverse) | |
| COX 7 | 5′- AAAGCGCACTAAATCGTCTCC-3′ (forward) |
| 5′- CATTCTATTCCGACTTGTGTTGCTA-3′ (reverse) | |
| COX 8 | 5′- TGTACTCCGTGCCATCATGT-3′ (forward) |
| 5′- TCACGAAGCAGGAGGTAAGC-3′ (reverse) | |
| β-actin | 5′-TCACCCACACTGTGCCCATCTACGA-3′ (forward) |
| 5′-GGATGCCACAGGATTCCATACCCA-3′ (reverse) |